Boardroom Alpha
Boardroom Alpha
TXMD · Additional Proxy Materials (DEFA14A) · Filed November 3, 2025

Therapeuticsmd Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
November 3, 2025
Ticker
TXMD
Accession
0001213900-25-105184
Boardroom Alpha · Filing insights

TherapeuticsMD's board urges shareholders to vote FOR Proposals 1, 2, 4 and 5 for an annual compensation advisory vote.

About Therapeuticsmd Inc
Market cap
$24M
1Y TSR
+73.9%
3Y TSR
−20.2%
Board grade
C-
Sector
Healthcare
CEO
Marlan D Walker
Last annual meeting: Dec 15, 2025 · View full Therapeuticsmd Inc profile →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

________________________

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.    )

________________________

Filed by the Registrant

 

 

Filed by a party other than the Registrant

 

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under §240.14a-12

TherapeuticsMD, Inc.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

C/O TABULATOR, P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! TherapeuticsMD, Inc. Annual Meeting of Stockholders Monday, December 15, 2025 8:00 AM, Eastern Time Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/TXMD for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/TXMD For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/TXMD To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before December 5, 2025. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On December 15, 2025 For Stockholders of Record as of October 20, 2025 To order paper materials, use one of the following methods. Internet: www.investorelections.com/TXMD Call: 1-866-648-8133 Email: paper@investorelections.com If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved

 

TherapeuticsMD, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2, 4 AND 5 THE BOARD RECOMMENDS THAT AN ADVISORY VOTE ON THE COMPENSATION FOR NAMED EXECUTIVE OFFICERS BE HELD EVERY 1 YEAR. PROPOSAL 1. To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified; 1.01 Tommy G. Thompson 1.02 Cooper C. Collins 1.03 Gail K. Naughton, Ph.D. 1.04 Justin Roberts 2. To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2024; 3. To provide a non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our named executive officers; 4. To ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP, an independent registered public accounting firm, as the independent auditor of our Company for the fiscal year ending December 31, 2025; 5. To approve an amendment to our Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock, $0.001 par value per share, to 640,000,000 shares; 6. To transact such other business as may properly come before the meeting or any adjournment thereof.

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Therapeuticsmd Inc (TXMD)

Reference

Frequently asked questions

When did Therapeuticsmd Inc file this DEFA14A?
Therapeuticsmd Inc (TXMD) filed this Additional Proxy Materials (DEFA14A) with the SEC on November 3, 2025. The accession number assigned by EDGAR is 0001213900-25-105184.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
TherapeuticsMD's board urges shareholders to vote FOR Proposals 1, 2, 4 and 5 for an annual compensation advisory vote. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Therapeuticsmd Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Therapeuticsmd Inc has filed under CIK 25743, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer